4.87

2.99% -0.15

After Hours: 4.88 0.010 +0.21%

Sellas Life Sciences Group Inc (SLS)

Overview News Price History Option Chain Financials Why SLS Down? Discussions Forecast Stock Split

Sellas Life Sciences Group Inc stock is traded at $4.87, with a volume of 2.84M. It is down -2.99% in the last 24 hours and up +17.92% over the past month. SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Previous Close:

$5.02

Open:

$5.05

24h Volume:

2.84M

Relative Volume:

0.47

Market Cap:

$898.67M

Revenue:

Net Income/Loss:

$-26.86M

P/E Ratio:

-19.81

EPS:

-0.2458

Net Cash Flow:

$-28.39M

1W Performance:

-0.20%

1M Performance:

+17.92%

6M Performance:

+189.88%

1Y Performance:

+184.80%

1-Day Range:

$4.825

$5.055

1-Week Range:

$4.655

$5.235

52-Week Range:

$1.36

$6.14

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name

Sellas Life Sciences Group Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(646) 200-5278

Address

7 TIMES SQUARE, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLS Sellas Life Sciences Group Inc	4.87	926.35M	0	-26.86M	-28.39M	-0.2458
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-21-21	Initiated	Cantor Fitzgerald	Overweight
Nov-01-18	Initiated	Oppenheimer	Outperform
Apr-02-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Stock (SLS) Latest News

May 05, 2026

SLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvals - MSN

May 05, 2026

May 04, 2026

SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits

May 04, 2026

May 03, 2026

SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN

May 03, 2026

May 02, 2026

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits

May 02, 2026

SLS stock gains momentum: NVDA, MSFT investor loads up ahead of AML trial milestone trigger - MSN

May 02, 2026

May 01, 2026

Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN

May 01, 2026

SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

May 01, 2026

Apr 30, 2026

SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN

Apr 30, 2026

SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN

Apr 30, 2026

SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

Apr 30, 2026

Apr 29, 2026

SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN

Apr 29, 2026

SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN

Apr 29, 2026